Untreated lung cancer has a high mortality rate with 95% patients dying within 1year. Treatment for NSCLC is planned according to the clinico-radiological stage, cardio-pulmonary reserve, performance status and includes multimodality treatment. Early-stage NSCLC is treated with surgery and adjuvant ...
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent kind of lung cancer with around 85% of total lung cancer cases. Despite vast therapies being available, the survival rate is low (5 year survival rate is 15%) making it essential to comprehend the mechanism for NSCLC cell survival a...
4) cell death rate 细胞死亡速率5) non-small-cell lung 非小细胞肺 1. Therapeutic evaluation of the combined chemotherapy of docetaxel and oxaliplatin in the treatment of non-small-cell lung cancer; 艾素联合艾恒治疗晚期非小细胞肺癌的疗效评价 2. Inhibitors of epidermal growth factor receptor ...
Pneumonectomy for non-small cell lung cancer: predictors of early mortality and morbidity. Acta Chir Belg 2014; 114: 25-30.Stolz AJ, Harustiak T, Simonek J, et al. Pneumonec- tomy for non-small cell lung cancer: predictors of early mortality and morbidity. Acta Chir Belg 2014; 114: ...
[Non-small cell bronchogenic can- cer in stage IA: mortality patterns after surgery]. Arch Bronconeumol 2005;41:180-184.Padilla J, Penalver JC, Jorda C, Calvo V, Escriva J, Ceron J, Garcia Zarza A, Pastor J, Blasco E. [Non-small cell bronchogenic cancer in stage IA: mortality ...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
In an ongoing, open-label, single-arm phase II study ( NCT02927301 ), 181 patients with untreated, resectable, stage IB–IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathologi
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death. Developing minimally invasive techniques that can diagnose NSCLC, particularly at an early stage, may improve its outcome. Using microarray platforms, we previously identifi
The connection between the exposure and lung cancer risk might be increased by a GSTMI-null genotype as well as overexertion of the p53 protein6,7. Even after a stove improvement project was done in the late 1980s, although the mortality rate of some regions in Xuanwei started to decline...